|
|
|
IBCSG 35-07 (SOLE)
A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive, node-positive early stage breast cancer.
Study Of Letrozole Extension (SOLE)
DESIGN
|
Study ChairsDr. Marco Colleoni - Milano, Italy
StatisticiansProf. Richard Gelber
Dr. Meredith Regan
Trial CoordinatorsMary Caporale, Tara Scolese
IBCSG Data Management Center/FSTRF 4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 836 6097
Email: ibcsg35_SOLE@fstrf.org
Date of ActivationNovember 8, 2007
Targeted Accrual4800 patients
News
01.02.2010:
The impact of peritumoral vascular invasion on outcome in IBCSG Trials VIII and IX
27.01.2010:
First issue of SOLE flash, the short newsletter for IBCSG 35-07 SOLE
11.01.2010:
The latest information about the IBCSG Annual Meeting 2010 is available online.
All News
|
|